Camurus’ Interim Report Second Quarter 2020
”For the fourth quarter in a row, we saw Buvidal® sales growth of more than 50%” Summary second quarter 2020 · Net revenues amounted to SEK 80.9 million (11.9), an increase of 579% · Net product sales totaled SEK 75.8 million (11.3), an increase of 568% · Product sales increased by 56% compared to the previous quarter · Net revenue for the period January to June amounted to SEK 130.2 million (30.4) and product sales SEK 124.4 million (22.3) · The full year 2020 guidance for revenue and product sales was raised · Buvidal® reimbursed in Sweden after a positive TLV